Food sensitisation patterns measured by ISAC multiplex assay in the Netherlands
© Blankestijn et al; licensee BioMed Central Ltd. 2015
Published: 30 March 2015
Component-resolved diagnostics is increasingly used in food allergy diagnostics. In a Dutch tertiary patient population we determined the sensitization patterns and protein families involved in our population using the multiplex Immuno-Solid phase Allergen Chip (ISAC).
Multiplex ISAC tests were performed in case of suspicion of (extensive) poly-sensitization in patients referred for food allergy and/or atopic eczema. Patient history of 40 random patients who have had an ISAC was analysed to determine the clinical value of the ISAC.
Of 943 ISAC tests, 852 showed sensitization to at least one component and were included for further analysis. Mean age was 33,4 years. The majority of patients in our population was poly-sensitized, with 66% recognizing more than ten components. The most recognized component was Bet v 1 (70%). The top 10 food allergens were: apple (Mal d 1; 65%), peach (Pru p 1; 63%), hazelnut (Cor a 1.0401; 63%), peanut (Ara h 8; 56%, Ara h 6; 23%, Ara h 2; 15%), soy (Gly m 4; 39%), celery (Api g 1; 25%), kiwi (Act d 8; 20%) and walnut (Jug r 2; 15%). 84% showed sensitization to one or more food allergens. Within this group, 84% recognized at least one PR-10 component, followed by storage proteins (35%) and non-specific lipid transfer proteins (nsLTP; 12%). The prevalence of sensitization to cross-reactive carbohydrate determinants (CCD) within the entire population was 9%. Sensitization to at least one food components of animal origin (cow's milk/egg) was seen in 19% of all cases, with Bos d 8 recognized most frequently (8.1%). The ISAC seems to support clinical suspicion of food allergy in most cases, although sensitization together with a negative patient history is common.
Bet v 1 is the allergen component recognized the most, followed closely by other PR-10 family proteins from plant foods. Sensitization to food components of animal origin was seen in 19% of the patients.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.